Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2596466 | 0.82 | P2RX4 (0.45) | P2RX4CHRM3CHRM2CHRM1ALOX5 | |
| SCHEMBL27661810 | 0.80 | CHRM3 (0.52) | CHRM3CHRM2CHRM1MEN1KMT2A | |
| SCHEMBL3245527 | 0.79 | THRB (0.59) | CHRM3CHRM2CHRM1ALDH1A1MAPT | |
| SCHEMBL29663083 | 0.79 | THRB (0.59) | CHRM3CHRM2CHRM1ALDH1A1MAPT | |
| SCHEMBL11996613 | 0.78 | P2RX4 (0.41) | P2RX4ALOX5ALDH1A1MAPTITGA4 | |
| SCHEMBL4221762 | 0.78 | P2RX4 (0.41) | P2RX4CHRM3CHRM2CHRM1ALOX5 | |
| SCHEMBL4636623 | 0.77 | THRB (0.41) | P2RX4CHRM3CHRM2CHRM1ALOX5 | |
| SCHEMBL524491 | 0.77 | THRB (0.61) | P2RX4CHRM3CHRM2CHRM1ALOX5 | |
| SCHEMBL4223414 | 0.77 | P2RX4 (0.41) | P2RX4CHRM3CHRM2CHRM1ALOX5 | |
| Bromomethane SCHEMBL208816 | 0.76 | THRB (0.55) | P2RX4CHRM3CHRM2CHRM1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115108901-A | Synthetic method of alpha-hydroxycarboxylic acid compound | 四川大学 | 2022-09-27 | — | — | CN | disclosed |
| WO-2010071582-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A SECOND ACTIVE INGREDIENT | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010071581-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A B2-ADRENOCEPTOR AGONIST | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | WO | disclosed |
| WO-2009139710-A1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | WO | disclosed |
| US-20090155185-A1 | MEDICAMENTS FOR INHALATION COMPRISING AN ANTICHOLINERGIC AND A BETAMIMETIC | MEADE CHRISTOPHER JOHN MONTAGUE | 2009-06-18 | — | — | US | disclosed |
| WO-2008149110-A1 | BICYCLOR [2.2.1] HEPT-7-YLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES AND CONDITIONS IN WHICH M3 MUSCARINIC RECEPTOR ACTIVITY AND BETA-ADRENERGIC ACTIVITY ARE IMPLICATED | ARGENTA DISCOVERY LIMITED (GB) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008096127-A2 | BICYCLO[2.2.1]HEPT-7-YLAMINE DERIVATIVES AND THEIR USE AS M3 MUSCARINIC RECEPTOR MODULATORS | ARGENTA DISCOVERY LTD (GB) | 2008-08-14 | — | — | WO | disclosed |
| US-7405224-B2 | Xanthenecarboxylates, processes for preparing them, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2008-07-29 | — | — | US | disclosed |
| CN-1291986-C | Anticholinergic agents, method for the production thereof and use thereof as medicaments | BOEHRINGER INGELHEIM PHARMA (DE) | 2006-12-27 | — | — | CN | disclosed |
| EP-1651224-A1 | MEDICAMENTS FOR INHALATION COMPRISING ANTICHOLINERGICS AND A BETAMIMETIC | Boehringer Ingelheim International GmbH (DE) | 2006-05-03 | — | — | EP | disclosed |
| CN-1625556-A | Anticholinergic agents, method for the production thereof and use thereof as medicaments | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-06-08 | — | — | CN | disclosed |
| WO-2005013994-A1 | MEDICAMENTS FOR INHALATION COMPRISING ANTICHOLINERGICS AND A BETAMIMETIC | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-17 | — | — | WO | disclosed |
| US-20050025718-A1 | Medicaments for inhalation comprising an anticholinergic and a betamimetic | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-03 | — | — | US | disclosed |
| US-20030203928-A1 | Xanthenecarboxylates, processes for preparing them, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH CO. KG (DE) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155185-A1 | MEDICAMENTS FOR INHALATION COMPRISING AN ANTICHOLINERGIC AND A BETAMIMETIC | ADRB2, CHRM3, ADRB1 | P2RX4 2671/4885CHRM3 2/4885CHRM2 4/4885 |
| US-20030203928-A1 | Xanthenecarboxylates, processes for preparing them, and their use as pharmaceutical compositions | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, F11, NR3C2 | P2RX4 3934/4885CHRM3 262/4885CHRM2 334/4885 |
| US-20050025718-A1 | Medicaments for inhalation comprising an anticholinergic and a betamimetic | ADRB2, CHRM3, ADRB1 | P2RX4 2671/4885CHRM3 2/4885CHRM2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.